Phase 1
N=12
Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)
Human Immunodeficiency Virus (HIV) Infection
Bottom Line
View on ClinicalTrials.gov: NCT04303156 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Oct 2021
Primary outcome: Primary: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL) — 14.4; 6.54 hr*μM
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- Islatravir (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Merck Sharp & Dohme LLC
- Primary completion
- Oct 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL) |
14.4; 6.54 | — |
| PRIMARY Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Plasma ISL |
11.0; 5.68 | — |
| PRIMARY Maximum Concentration (Cmax) of Plasma ISL |
1.23; 1.19 | — |
| PRIMARY Time of Maximum Concentration (Tmax) of Plasma ISL |
1.03; 0.75 | — |
| PRIMARY Apparent Terminal Half-life (t1/2) of Plasma ISL |
127; 72.0 | — |
| PRIMARY Apparent Clearance (CL/F) of Plasma ISL |
14.2; 31.3 | — |
| PRIMARY Apparent Volume of Distribution (Vz/F) of Plasma ISL |
2610; 3250 | — |
| SECONDARY AUC0-inf of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMC) |
5810; 3920 | — |
| SECONDARY AUC0-last of ISL-TP in PBMC |
5200; 3780 | — |
| SECONDARY Cmax of ISL-TP in PBMC |
20.3; 21.6 | — |
| SECONDARY Tmax of ISL-TP in PBMC |
36.00; 24.00 | — |
| SECONDARY Concentration at 24 Hours Post Dose (C24) of ISL-TP in PBMC |
18.4; 19.0 | — |
| SECONDARY Concentration at 168 Hours Post Dose (C168) of ISL-TP in PBMC |
8.06; 4.43 | — |
| SECONDARY Concentration at 672 Hours Post Dose (C672) of ISL-TP in PBMC |
1.96; 0.730 | — |
| SECONDARY T1/2 of ISL-TP in PBMC |
181; 131 | — |
| SECONDARY Percentage of Participants With an Adverse Event (AE) |
16.7; 0.0 | — |
| SECONDARY Percentage of Participants Who Discontinued From the Study Due to an AE |
0.0; 0.0 | — |
Summary
This study will evaluate the general tolerability and pharmacokinetics (PK) of a single 60 mg dose of MK-8591 (Islatravir) in participants with severe renal insufficiency, compared to participants in good health.
Eligibility Criteria
Inclusion Criteria
Healthy participants must have the following:
- Is in good health
- Has a body mass index (BMI) ≥18.5 and ≤40 kg/m2.
- Female is not pregnant or breastfeeding, and is not one of the following: a woman of childbearing potential (WOCBP); if a WOCBP, is using an acceptable contraceptive method, or is abstinent from heterosexual intercourse as their preferred and usual lifestyle; a WOCBP must have a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention
Renally impaired participants must have the following:
- With the exception of renal impairment, is in generally good health
- Has a BMI ≥ 18.5 and ≤ 40 kg/m2
- Female is not pregnant or breastfeeding, and is not one of the following: a woman of childbearing potential (WOCBP); if a WOCBP, is using an acceptable contraceptive method, or is abstinent from heterosexual intercourse as their preferred and usual lifestyle; a WOCBP must have a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention
Exclusion Criteria
Healthy participants must have the following:
- Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
- Is mentally or legally incapacitated, has significant emotional problems
- Has known hypersensitivity to the active substance or any of the excipients of the study drug
- Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e. systemic allergic reaction) to prescription or non-prescription drugs or food.
- Is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV.
- Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within prior 4 weeks
- Is taking medications to treat chronic medical conditions and/or conditions associated with renal disease
- Has participated in another investigational study within prior 4 weeks
Other exclusions for healthy participants:
- Does not agree to follow the smoking restrictions
- Consumes greater than 1 glass for women, or 2 glasses for men of alcoholic beverages per day
- Consumes excessive amounts, of caffeinated beverages per day.
- Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately prior 3 months.
Renally impaired participants must have the following:
- Has a history or presence of renal artery stenosis.
- Has had a renal transplant or nephrectomy.
- Has rapidly fluctuating renal function as determined by historical measurements.
- Has known hypersensitivity to the active substance or any of the excipients of the study drug.
- Has a history of cancer (malignancy).
- Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e. systemic allergic reaction) to prescription or non-prescription drugs or food.
- Is positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV).
- Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
- Is taking medications to treat chronic medical conditions and/or conditions associated with renal disease and has not been on a stable regimen for at least 1 month and/or is unable to withhold the use of the medication(s) within 4 hours prior to and 8 hours after administration of the study drug.
- Has participated in another investigational study within 4 weeks (or 5 half-lives, whichever is greater) prior to the prestudy (screening) visit.
Other exclusions for renally impaired participants
- Does not agree to follow the smoking restrictions.
- Consumes greater than 1
Data sourced from ClinicalTrials.gov (NCT04303156). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.